Actively Recruiting
Phase 1 Study Comparing How HSK39297 Works and its Safety in Adults with Mild to Moderate Liver Impairment and Those with Normal Liver Function
Led by Haisco Pharmaceutical Group Co., Ltd. · Updated on 2025-09-03
24
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the pharmacokinetics, safety, and pharmacodynamics of the drug HSK39297 in adults aged 18 to 70 years with mild to moderate liver impairment compared to those with normal liver function. This Phase 1, open-label study aims to better understand how the drug behaves in different liver health conditions to inform future use. The study is sponsored by Haisco Pharmaceutical Group Co., Ltd. Participants will receive a single oral dose of HSK39297 and be assigned to one of three groups mild hepatic impairment, moderate hepatic impairment, or normal liver function. The study monitors drug concentration over 10 days post-dose and includes groups matched by age, sex, and body mass index to ensure comparability. Subjects with liver impairment must meet specific criteria including stable medication use and Child-Pugh classification. During the study, participants will undergo physical exams, vital sign checks, ECGs, imaging, and laboratory tests before and after dosing. Researchers will measure drug levels including peak concentration Cmax, area under the curve AUC, and other pharmacokinetic parameters from day 1 to day 10. Safety will be monitored by recording adverse events throughout the screening and follow-up periods. The total commitment covers screening and 10 days post-dose observation.
CONDITIONS
Brief Title
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment
Research Team
C
Chen Meixia
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here